Cytomegalovirus
Antisense Drug Targeted at CMV Infection Tested in Europe
Published in AIDS Weekly, July 8th, 1996
New data on its first clinical compound, GEM 91, a planned Investigational New Drug (IND) filing for a compound targeted at cytomegalovirus (CMV) disease, and the first commercial-scale manufacturing of synthetic DNA.
The highlight of the 1996 midyear progress report was the announcement that Hybridon has planned to start clinical trials in Europe in the Summer 1996 of GEM 132, a genetic antisense compound for patients with CMV disease. This trial involves systemic administration of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1996-07-08)
More Articles from AIDS Weekly
- Conference Coverage (IBC Protease Inhibitors)
Agouron Protease Inhibitor Enters Triple Combination Trials - Conference Coverage (IBC Protease Inhibitors)
Ritonavir Combinations Shine in Early Studies - Conference Coverage (IBC Protease Inhibitors)
Roche Researcher: Saquinavir Safe, Active in 3TC/AZT Combination - Conference Overview (XI Int Conf on AIDS)
AIDS Now A Manageable Disease - For Those Who Can Afford It - AIDS Therapies
Two Combination Regimens Shown To Be Advantageous in AIDS Patients - AIDS Therapies (Lamivudine)
Renal Dysfunction Affects Pharmacokinetics - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
